Related Experiment Video
Updated: May 22, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Tiagabine add-on for drug-resistant partial epilepsy
Jennifer Pulman1, Anthony G Marson, Jane L Hutton
1Department of Molecular and Clinical Pharmacology, Cochrane Epilepsy Group, Liverpool, UK. jennifer.pulman@liv.ac.uk.
The Cochrane Database of Systematic Reviews
|May 18, 2012
Summary
Tiagabine as an add-on therapy significantly reduces seizure frequency in drug-resistant epilepsy. However, it is associated with adverse effects like dizziness and fatigue, impacting treatment adherence.
Area of Science:
- Neurology
- Pharmacology
Background:
- Epilepsy affects 0.5-1% of the population, with nearly 30% exhibiting drug resistance.
- Tiagabine is a newer antiepileptic drug evaluated as an adjunct therapy.
Purpose of the Study:
- To assess tiagabine's efficacy and safety as an add-on treatment for drug-resistant localisation-related seizures.
- Evaluate effects on seizure frequency, adverse events, cognition, and quality of life.
Main Methods:
- Systematic review and meta-analysis of randomized placebo-controlled add-on trials.
- Searched Cochrane Epilepsy Group Register, CENTRAL, and MEDLINE up to November 2011.
- Included trials with a minimum eight-week treatment period; data extracted independently.
Main Results:
- Tiagabine significantly increased the likelihood of a 50% or greater seizure frequency reduction (RR 3.16).
- Higher treatment withdrawal rates were observed with tiagabine (RR 1.81).
- Significantly associated adverse effects included dizziness, fatigue, nervousness, and tremor.
Conclusions:
- Tiagabine is effective in reducing seizure frequency in drug-resistant epilepsy.
- Adverse effects are a concern and may impact treatment continuation.
- Limited data suggest no significant impact on cognition or quality of life.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...